MMI-0100

MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II ( MK2 ). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease. In Vitro Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner.. MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone. MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100. MMI-0100 does not induce EC apoptosis at any dose. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: human endothelial cell (EC) and smooth muscle cell (SMC) Concentration: 0.25, 0.5, and 1 mM Incubation Time: 24 hours Result: Slightly increased cell proliferation in both cell types compared to control cells. In Vivo MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 12-week-old C57Bl/6 wild type mice (intimal hyperplasia) Dosage: 100 μM Administration: vein graft, 28 days Result: Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet